Division of General Internal Medicine, University of Pennsylvania, 423 Guardian Drive, Philadelphia, PA 19104, USA.
Prev Med. 2012 Nov;55 Suppl:S41-5. doi: 10.1016/j.ypmed.2012.06.013. Epub 2012 Jun 23.
The aim of this study is to assess public support for a smoking cessation policy involving financial incentives.
We conducted a randomized controlled trial using an experimental survey design. One of four questionnaire versions was distributed to participants. Each version described a smoking cessation treatment costing $750 per success, including an unspecified treatment, medication, or financial incentive paid to the smoker. Participants indicated whether they would support a $25 increase in their annual health insurance premium to pay for the treatment. Questionnaires were distributed to adults waiting at public transportation depots in Philadelphia between May and August 2010.
1010 individuals completed the questionnaires about willingness to support the policy: 53% female, 27% African-American, 18% current smokers, and 46% with a household income below $40,000. The response rate was greater than 50%. Overall support for all smoking cessation treatments was 41.6%. The financial incentive version received the lowest support (39.3%) but that support did not statistically differ from the treatment (45.8%, p=0.14) or medication (41.7%, p=0.58) versions.
Financial incentives were perceived no differently than currently used medications for smoking cessation. Most participants did not support any smoking cessation treatment options.
本研究旨在评估公众对涉及经济激励的戒烟政策的支持程度。
我们采用随机对照试验和实验调查设计进行了研究。将四个问卷版本之一分发给参与者。每个版本都描述了一种戒烟治疗方法，成本为每次成功治疗 750 美元，其中包括未指定的治疗、药物或支付给吸烟者的经济激励。参与者表示是否愿意支付每年健康保险费增加 25 美元来支付治疗费用。问卷于 2010 年 5 月至 8 月在费城公共交通枢纽处等候的成年人中分发。
1010 名个体完成了有关政策支持意愿的问卷：53%为女性，27%为非裔美国人，18%为当前吸烟者，46%的家庭收入低于 40,000 美元。回应率大于 50%。对所有戒烟治疗方法的总体支持率为 41.6%。经济激励版本的支持率最低（39.3%），但与治疗（45.8%，p=0.14）或药物（41.7%，p=0.58）版本相比，支持率没有统计学差异。
经济激励措施与目前用于戒烟的药物没有区别。大多数参与者不支持任何戒烟治疗方案。
